CTLA4 and neoplasm: In patients receiving another CTLA-4 abrogating antibody, tremelimumab, the ratio of intratumoral T cells to FoxP3 positive T regulatory cells was increased after treatment only in regressing lesions [30], suggesting a therapeutic impact of CTLA-4 abrogation on T cells infiltrating the tumor.